AbbVie (ABBV) slides as investors weigh policy-related pricing risk and recent financing activity

AbbVie Inc. (ABBV) is down 3.3% today. Here is some analysis on what might have caused this price movement.

Analysis: There was no single, widely-circulated company-specific headline tied to today’s decline, so the catalyst looks more like a sentiment-driven pullback. This could be linked to renewed focus on U.S. drug-pricing/discount-channel risk and light profit-taking after recent company updates (guidance and debt financing) that didn’t add a fresh upside surprise.

Details:

AbbVie’s most recent earnings update reiterated full-year 2026 adjusted EPS guidance of $14.37 to $14.57, setting expectations that are now being continuously re-underwritten by the market.

AbbVie recently completed a multi-tranche senior notes offering (disclosed via an 8-K/indenture materials), a reminder that leverage and interest expense remain part of the equity story even as cash flows are strong.

A recent federal appeals-court decision upheld Louisiana’s 340B contract-pharmacy discount law in a case involving AbbVie and other industry plaintiffs, keeping attention on gross-to-net and channel-pricing pressure.

Separately, Medicare-negotiated prices scheduled to take effect in 2026 for select drugs have kept the broader “pricing reset” narrative active for large-cap pharma names.

Sources:

AbbVie Investor Relations, U.S. SEC (EDGAR), Becker’s Hospital Review

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ABBV Insider Trading Activity

$ABBV insiders have traded $ABBV stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:

PERRY C SIATIS (EVP, GC AND SECRETARY) has made 0 purchases and 3 sales selling 18,668 shares for an estimated $4,375,549.
DAVID RYAN PURDUE (SVP, Controller) sold 5,230 shares for an estimated $1,221,518

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$ABBV Hedge Fund Activity

We have seen 1,768 institutional investors add shares of $ABBV stock to their portfolio, and 1,866 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 37,400,173 shares (-74.3%) from their portfolio in Q4 2025, for an estimated $8,545,565,528
CAPITAL WORLD INVESTORS added 6,736,161 shares (+106.3%) to their portfolio in Q4 2025, for an estimated $1,539,145,426
BLACKROCK, INC. added 5,197,454 shares (+3.6%) to their portfolio in Q4 2025, for an estimated $1,187,566,264
CARDANO RISK MANAGEMENT B.V. added 4,908,260 shares (+914.6%) to their portfolio in Q4 2025, for an estimated $1,121,488,327
WELLINGTON MANAGEMENT GROUP LLP added 4,389,782 shares (+41.7%) to their portfolio in Q4 2025, for an estimated $1,003,021,289
GEODE CAPITAL MANAGEMENT, LLC added 4,190,487 shares (+10.4%) to their portfolio in Q4 2025, for an estimated $957,484,374
JPMORGAN CHASE & CO removed 4,141,493 shares (-7.3%) from their portfolio in Q4 2025, for an estimated $946,289,735

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ABBV Government Contracts

We have seen $321,434 of award payments to $ABBV over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

PROSTHETIC ORDER - IMPLANT ITEMS: $15,758
4567881995!NATRELLE TE SMOOTH 133S-MV-15-T: $13,170
4567953518!NATRELLE INSPIRA SSL 230CC BREAST IMPLAN: $12,888
BREAST IMPLANTS: $10,935
4568645077!NATRELLE TE SMOOTH 133S-MV-11-T: $9,109

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$ABBV Congressional Stock Trading

Members of Congress have traded $ABBV stock 6 times in the past 6 months. Of those trades, 1 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:

REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.
REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 12/08.
REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$ABBV Analyst Ratings

Wall Street analysts have issued reports on $ABBV in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HSBC issued a "Buy" rating on 12/10/2025
Guggenheim issued a "Buy" rating on 10/20/2025
Piper Sandler issued a "Overweight" rating on 10/10/2025

To track analyst ratings and price targets for $ABBV, check out Quiver Quantitative's $ABBV forecast page.

$ABBV Price Targets

Multiple analysts have issued price targets for $ABBV recently. We have seen 14 analysts offer price targets for $ABBV in the last 6 months, with a median target of $255.5.

Here are some recent targets:

Trung Huynh from RBC Capital set a target price of $260.0 on 02/25/2026
Emily Field from Barclays set a target price of $275.0 on 02/20/2026
David Amsellem from Piper Sandler set a target price of $299.0 on 02/18/2026
Michael Yee from UBS set a target price of $230.0 on 02/05/2026
Gavin Clark-Gartner from Evercore ISI Group set a target price of $228.0 on 02/05/2026
Terence Flynn from Morgan Stanley set a target price of $270.0 on 02/05/2026
Geoff Meacham from Citigroup set a target price of $230.0 on 01/27/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.